Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Phase 3

Active, not recruiting

• Conditions: Acute Myelogenous Leukemia; Leukemia, Acute Myelogenous; Acute Myeloid Leukemia; Leukemia, Myeloid, Acute; Myelogenous Leukemia, Acute; AML; Myeloid Leukemia, Acute; Bone Marrow Transplant; Leukemia, Acute Myeloid
• Interventions: Drug: Iomab-B; Drug: Conventional Care; Procedure: HCT

• Registration Number: NCT02665065
• Lead Sponsor: Actinium Pharmaceuticals

Brief Summary

The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (AML).

Detailed Description

SIERRA is a pivotal Phase 3 randomized controlled study of Iomab-B in Relapsed or Refractory AML patients. The SIERRA trial has a primary endpoint of durable Complete Remission (dCR) at six months and a secondary endpoint of overall survival following randomization to Iomab-B, as well as Event-Free Survival. Iomab-B is intended to prepare and condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, in a potentially safer and more efficacious manner than intensive chemotherapy conditioning that is the current standard of care in bone marrow transplant conditioning.

Study Timeline

• Study First Submitted: 2016-01-22
• Study First Submitted QC: 2016-01-26
• Study First Posted: 2016-01-27
• Study Start: 2016-06
• Primary Completion: 2022-06
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-18
• Last Update Posted: 2023-07-19
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 153

Inclusion Criteria

• Have active, relapsed or refractory Acute Myeloid Leukemia (AML). Active, relapsed or refractory AML is defined as any one of the following (1) primary induction failure, or (PIF) after 2 or more cycles of therapy, or (2) first early relapse after a remission duration of fewer than 6 months, or (3) relapse refractory to salvage combination chemotherapy, or (4) second or subsequent relapse
• Have documented CD45 expression by leukemic cells via flow cytometry (a "blast gate" on CD45 vs. side scatter analysis consistent with AML)
• Be at least 55 years of age
• Have a circulating blast count of less than 10,000/mm3 (control with hydroxyurea is allowed)
• Have a calculated creatinine clearance (Cockcroft-Gault equation) > 50 mL/min
• Have adequate hepatic function (direct bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT), defined as ≤ 2 times the upper limit of normal [ULN])
• Have a Karnofsky score ≥ 70
• Have an expected survival of > 60 days
• Have a central venous catheter line in place prior to study treatment administration
• Have 8/8 allele-level, related or unrelated, medically cleared HSC donor matching at human leukocyte antigen (HLA)-A, HLA-B, HLA-C, and DRB-1 with a donor who is medically cleared. Syngeneic donors that meet these criteria are allowed
• Women of childbearing potential, be surgically sterile or agree to practice abstinence or utilize acceptable contraception (intrauterine, injectable, transdermal, or combination oral contraceptive) through 1-year post transplant; Males who are sexually active with women of childbearing potential must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) from time of screening through 12 weeks after last dose of study drug
• Be able to understand the study procedures, agree to participate in the study program, and voluntarily provide written Informed Consent

Read More

Exclusion Criteria

• Have circulating HAMA noted on initial screening
• Have received prior radiation to maximally tolerated levels to any critical normal organ
• Have active leukemic central nervous system (CNS) involvement, as defined by any leukemic blasts detected in the cerebrospinal fluid (CSF) by morphology or flow cytometry and/or any chloromas detected by CNS imaging
• Have previously received HCT (including both allogeneic and autologous HCT)
• Have clinically significant cardiac disease (NYHA Class III or IV); clinically significant arrhythmia i.e. ventricular tachycardia, ventricular fibrillation, or "Torsade de Pointes". Myocardial infarction with uncontrolled angina within 6 months, congestive heart failure, or clinically significant cardiomyopathy
• Have abnormal QTcF (>450milliseconds) after electrolytes have been corrected (at least two different ECG readings and at least 15 minutes between readings). Subjects with paced rhythm or prolonged QTcF may be exempt from this exclusion if considered eligible for transplant per treating physician clinical judgement with optional cardiology consultation
• Have current or prior positive test results for human immunodeficiency virus (HIV) or hepatitis B (HBV) or C. Subjects who have positive HBV test results due to having been previously vaccinated against hepatitis B, as evidenced by negative hepatitis B surface antigen (HBsAg), negative anti- hepatitis B core protein (HBc) and positive antibody to the HBsAg (anti-HBs) are not excluded. Subjects who have positive hepatitis test results with adequate organ function as defined in the protocol are not excluded
• Have active serious infection uncontrolled by antibiotics or antifungals
• Have acute promyelocytic leukemia and the associated cytogenic translocation t(15/17)
• Have active malignancy within 2 years of entry. Active malignancy is defined as those malignancies requiring treatment with anti-cancer therapy or in the event of indolent malignancies, having measurable disease. Exceptions to this exclusion include: myelodysplastic syndrome, treated non-melanoma skin cancer, completely resected Stage 0 or 1 melanoma no less than 1 year from resection, carcinoma in situ or cervical intraepithelial neoplasia, and successfully treated organ-confined prostate cancer with no evidence of progressive disease based on prostate specific antigen (PSA) levels and are not on active therapy
• Have a perceived inability to tolerate diagnostic or therapeutic procedures, particularly treatment in radiation isolation
• Currently receiving any other active investigational agents

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Iomab-B	HCT	Iomab-B in conjunction with a Reduced Intensity Conditioning (RIC) regimen containing Fludarabine and low-dose Total Body Irradiation (TBI) prior to allogeneic HCT
Conventional Care	HCT	Defined as Investigator's choice of salvage chemotherapy with any combination of the following agents: Azacitidine (not allowed as a single agent), Carboplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin, Decitabine (not allowed as a single agent with the exception of patients with documented TP53 mutations who have not previously received 10-day regimens of single agent decitabine), Doxorubicin, Enasidenib, Etoposide, Fludarabine, Gemtuzumab ozogamicin, Idarubicin, Ivosidenib (for subjects with IDH1 mutation), L-Asparaginase, Midostaurin (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Mitoxantrone, Sorafenib (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Thioguanine, Topotecan, Venetoclax (in combination with a hypomethylating agent). Chemotherapy agents not listed above may be administered after providing clinical justification and receiving medical monitor approval prior to initiation of treatment.
Iomab-B	Iomab-B	Iomab-B in conjunction with a Reduced Intensity Conditioning (RIC) regimen containing Fludarabine and low-dose Total Body Irradiation (TBI) prior to allogeneic HCT
Conventional Care	Conventional Care	Defined as Investigator's choice of salvage chemotherapy with any combination of the following agents: Azacitidine (not allowed as a single agent), Carboplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin, Decitabine (not allowed as a single agent with the exception of patients with documented TP53 mutations who have not previously received 10-day regimens of single agent decitabine), Doxorubicin, Enasidenib, Etoposide, Fludarabine, Gemtuzumab ozogamicin, Idarubicin, Ivosidenib (for subjects with IDH1 mutation), L-Asparaginase, Midostaurin (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Mitoxantrone, Sorafenib (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Thioguanine, Topotecan, Venetoclax (in combination with a hypomethylating agent). Chemotherapy agents not listed above may be administered after providing clinical justification and receiving medical monitor approval prior to initiation of treatment.

Primary Outcome Measures

Name	Time	Method
Durable Complete Remission (dCR)	6 months from time of initial CR or CRp	Defined as CR or CRp lasting 180 days or more from time of initial CR or CRp is documented with evidence of subsequent relapse

Secondary Outcome Measures

Name	Time	Method
Overall Survival (OS) following randomization to Iomab-B versus Convetional Care	Over a 5 year period	Patient overall survival
Event-Free Survival	Over a 5 year period	Duration of time from randomization to the date of induction treatment failure (ITF), relapse or death

Trial Locations

Locations (23)

Loyola University Medical Center; 🇺🇸 Maywood, Illinois, United States

Stony Brook University; 🇺🇸 Stony Brook, New York, United States

Baylor Charles A. Sammons Cancer Center; 🇺🇸 Dallas, Texas, United States

The University of Kansas Cancer Center; 🇺🇸 Westwood, Kansas, United States

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada

University of Ottawa; 🇨🇦 Ottawa, Ontario, Canada

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Banner MD Anderson Cancer Center; 🇺🇸 Gilbert, Arizona, United States

Yale Cancer Center; 🇺🇸 New Haven, Connecticut, United States

Georgetown University Medical Center; 🇺🇸 Washington, District of Columbia, United States

University of Nebraska Medical Center; 🇺🇸 Omaha, Nebraska, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Oregon Health & Science University; 🇺🇸 Portland, Oregon, United States

Medical College of Wisconsin; 🇺🇸 Milwaukee, Wisconsin, United States

University of Iowa; 🇺🇸 Iowa City, Iowa, United States

Roswell Park Cancer Institute; 🇺🇸 Buffalo, New York, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

Weill Cornell Medicine; 🇺🇸 New York, New York, United States

University of North Carolina Hospital; 🇺🇸 Chapel Hill, North Carolina, United States

University Hospital of Cleveland Seidman Cancer Center; 🇺🇸 Cleveland, Ohio, United States

The Ohio State University Comprehensive Cancer Center; 🇺🇸 Columbus, Ohio, United States

Fred Hutchinson Cancer Research Center; 🇺🇸 Seattle, Washington, United States